Zhou Liu-yong, Shan Zhen-zhu, You Jian-liang
Department of Oncology, Wuxi Municipal Hospital of Traditional Chinese Medicine, Jiangsu Province, 214001, China.
Chin J Integr Med. 2009 Apr;15(2):107-11. doi: 10.1007/s11655-009-0107-y. Epub 2009 Apr 29.
To observe the clinical effect of combined chemotherapy and Chinese herbal medicine in treating colonic cancer.
One hundred and sixty-three patients were assigned, according to their will, to two groups, 105 in the traditional Chinese medicine treated group (Group A) and 58 in the combined treatment group (Group B). The Chinese herbal drug Zhao's Weitiao No. 3 ( 3, ZW3) was given to both groups, twice a day, 40 mL each time, 30 days as one cycle, and over 6 cycles applied in total. For patients in Group B, the chemotherapy of OLF protocol (L-OHP+LV+5-FU) was given for 4-6 cycles. The effects of treatment on the main symptoms, tumor mass, patients' quality of life (QOL) and body weight, changes of carcino-embryonic antigen (CEA), as well as the integral effect and survival rate were observed and compared.
The total effective rate in Group A and Group B was 89.52% and 86.21% respectively, on the main clinical symptoms; 86.67% and 93.10% on tumor mass, 82.86% and 77.59% on QOL, 85.71% and 75.86% on body weight and 76.19% and 79.31% on CEA. The integral efficacy of total beneficial rate was 73.33% and 68.97%; and the 3-year survival rate 49.52% and 46.65% in Group A and Group B. These data showed that the effect in Group A was better than in Group B in terms of clinical symptom improvement, QOL, body weight and integral beneficence increase and survival rate, though it was inferior in reducing the tumor mass and CEA level.
Chinese drug ZW3 for the treatment of colonic cancer could improve the main clinical symptoms, improve the QOL, increase body weight and prolong the survival time of patients, showing a favorable integral effect.
观察化疗联合中药治疗结肠癌的临床疗效。
163例患者根据意愿分为两组，中药治疗组（A组）105例，联合治疗组（B组）58例。两组均给予中药赵氏胃肠3号（ZW3），每日2次，每次40 mL，30天为1个周期，共应用6个周期以上。B组患者给予OLF方案（L-OHP+LV+5-FU）化疗4-6个周期。观察并比较两组治疗对主要症状、肿瘤肿块、患者生活质量（QOL）、体重、癌胚抗原（CEA）变化以及整体疗效和生存率的影响。
在主要临床症状方面，A组和B组的总有效率分别为89.52%和86.21%；肿瘤肿块方面分别为86.67%和93.10%；QOL方面分别为82.86%和77.59%；体重方面分别为85.71%和75.86%；CEA方面分别为76.19%和79.31%。总有效率的整体疗效分别为73.33%和68.97%；A组和B组的3年生存率分别为49.52%和46.65%。这些数据表明，A组在改善临床症状、QOL、体重、提高整体疗效和生存率方面优于B组，尽管在缩小肿瘤肿块和降低CEA水平方面不如B组。
中药ZW3治疗结肠癌可改善主要临床症状，提高QOL，增加体重，延长患者生存时间，显示出良好的整体疗效。
